Paris, 21 April 2010 – NYSE Euronext today announced the admission to NYSE Alternext of NEOVACS. NEOVACS is a leader in active immunotherapy with applications in autoimmune diseases, inflammatory conditions and cancer thanks to a new approach based on therapeutics called Kinoids®.
The admission of NEOVACS (mnemo: ALNEV) was by the listing of 8,424,600 existing shares making up its share capital and the issue of 2,084,636 new shares as part of a global offering. A further 2,346,605 new shares were created by the conversion of convertible bonds and exercise of equity warrants, setting the total amount raised at EUR 10,006,252.80. The admission and issue price of NEOVACS shares was set at EUR 4.80 each. The company’s capitalization on the day of admission amounted to EUR 61,708,036.80.